The Liver Meeting 2021-Advances in Management of Liver Masses

Video Transcription

Video Summary

In summary, the video transcript discusses the Hepatology Associates SIG program focusing on the management of liver masses. It covers the evaluation and diagnosis of liver lesions, management options including surgical resection, ablative techniques, liver transplantation, recent advances in local regional therapies, and systemic treatment options. The session presents a case study of a patient with hepatocellular carcinoma, highlighting the importance of BCLC staging in determining treatment strategies. It reviews first and second-line systemic chemotherapies, such as serafinib, limbatinib, and the combination of tazolizumab and bevacizumab. The transcript also explains the mechanisms of action, clinical trials, and side effects of these treatments. The efficacy of these treatments is demonstrated through survival rates ranging from 10 to 19 months, with options for patients who have progressed on prior therapies or are ineligible for specific treatments. The key takeaway points stress the importance of considering systemic therapies for patients who cannot undergo other treatment modalities, emphasizing the need for close monitoring of side effects. The session concludes by inviting questions for the presenters and inviting viewers to join the Hepatology Associates SIG for further engagement and information.

Keywords

Hepatology Associates SIG program

management of liver masses

liver lesions evaluation

surgical resection

ablative techniques

liver transplantation

local regional therapies

systemic treatment options

BCLC staging

systemic chemotherapies

clinical trials